Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. [electronic resource]
Producer: 20070928Description: 517-26 p. digitalISSN:- 0007-1048
- Adult
- Aged
- Alemtuzumab
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Disease-Free Survival
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Histocompatibility Testing
- Humans
- Leukemia, Myeloid, Acute -- mortality
- Male
- Middle Aged
- Myelodysplastic Syndromes -- mortality
- Prospective Studies
- Time Factors
- Transplantation Chimera
- Transplantation Conditioning -- methods
- Transplantation, Homologous
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.